Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 1, 2014, Pages 22-35

  Jane, Esther P ^a,b   Premkumar, Daniel R ^a,b   Morales, Alejandro ^b   Foster, Kimberly A ^a,b,c   Pollack, Ian F ^a,b,c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; APOPTOSIS INDUCING FACTOR; BIM PROTEIN; BUPARLISIB; CASPASE; CASPASE 3; CASPASE 8; CYTOCHROME C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BID; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN NOXA; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL FRACTIONATION; CELL PROLIFERATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA CONTENT; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME INHIBITION; ENZYME RELEASE; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; APOPTOSIS INDUCING FACTOR; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BIPHENYL COMPOUNDS; CASPASE 3; CASPASE 8; CASPASES; CELL DEATH; CELL LINE, TUMOR; CHROMOSOME SEGREGATION; CYTOCHROMES C; DNA DAMAGE; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MORPHOLINES; NITROPHENOLS; PHOSPHATIDYLINOSITOL 3-KINASE; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84903537523     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.212910     Document Type: Article

References (49)

1. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, and Peters M, et al. (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30:282-290.
2. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, and Letai A (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351-365. (Pubitemid 43668734
3. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, and Huang DC (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393-403. (Pubitemid 40193310
4. Chen S, Dai Y, Harada H, Dent P, and Grant S (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67:782-791. (Pubitemid 46192219
5. Cristofanon S and Fulda S (2012) ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis 3: e432.
6. DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114-123.
7. Debien E, Hervouet E, Gautier F, Juin P, Vallette FM, and Cartron PF (2011) ABT-737 and/or folate reverse the PDGF-induced alterations in the mitochondrial apoptotic pathway in low-grade glioma patients. Clin Epigenetics 2:369-381.
8. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, and Letai A (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117:112-121. (Pubitemid 46048458
9. Gil-Parrado S, Fernández-Montalván A, Assfalg-Machleidt I, Popp O, Bestvater F, Holloschi A, Knoch TA, Auerswald EA, Welsh K, and Reed JC, et al. (2002) Ionomycin-activated calpain triggers apoptosis. A probable role for Bcl-2 family members. J Biol Chem 277:27217-27226. (Pubitemid 34951738
10. Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, Korsmeyer SJ, and Shore GC (1998) Regulated targeting of BAX to mitochondria. J Cell Biol 143: 207-215. (Pubitemid 28480529
11. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, and Lock RB (2010) The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 77:483-494.
12. Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, and Pollack IF (2013) YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther 12:326-338.
13. Jane EP, Premkumar DR, and Pollack IF (2006) Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther 319:1070-1080.
14. Jane EP, Premkumar DR, and Pollack IF (2011) Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-kappaB signaling pathway. Mol Cancer Ther 10:198-208.
15. Kitchens CA, McDonald PR, Shun TY, Pollack IF, and Lazo JS (2011) Identification of chemosensitivity nodes for vinblastine through small interfering RNA highthroughput screens. J Pharmacol Exp Ther 339:851-858.
16. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, and Sneed T, et al. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388. (Pubitemid 44693472
17. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, and Schlesinger PH (2000) Proapoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 7:1166-1173. (Pubitemid 32042223
18. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, and Yuan Y, et al. (2012) Antitumor activity of NVP-BKM120-A selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18:184-195.
19. Li H, Zhu H, Xu CJ, and Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501. (Pubitemid 28391865
20. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B, and Andrews DW (2008) Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135:1074-1084.
21. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, and DePinho RA (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15:1311-1333. (Pubitemid 32524640
22. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, and Wiesmann M, et al. (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11:317-328.
23. Martinou JC and Green DR (2001) Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2:63-67.
24. Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S, Belka C, Brossart P, Patrone F, and Ballestrero A (2005) Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res 11:4259-4265. (Pubitemid 40791593
25. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, and Hajduk PJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681. (Pubitemid 40825512
26. Pollack IF (1994) Brain tumors in children. N Engl J Med 331:1500-1507.
27. Premkumar DR, Arnold B, Jane EP, and Pollack IF (2006a) Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells. Mol Carcinog 45:47-59. (Pubitemid 43122369
28. Premkumar DR, Arnold B, and Pollack IF (2006b) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth. Mol Carcinog 45:288-301.
29. Premkumar DR, Jane EP, Agostino NR, DiDomenico JD, and Pollack IF (2013a) Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog 52:118-133.
30. Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, and Pollack IF (2012) ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther 341:859-872.
31. Premkumar DR, Jane EP, Foster KA, and Pollack IF (2013b) Survivin inhibitor YM-155 sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. J Pharmacol Exp Ther 346:201-210.
32. Premkumar DR, Jane EP, and Pollack IF (2010) Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines. Int J Oncol 37:633-643.
33. Qian J, Zou Y, Rahman JS, Lu B, and Massion PP (2009) Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther 8:101-109.
34. Ren H, Chen M, Yue P, Tao H, Owonikoko TK, Ramalingam SS, Khuri FR, and Sun SY (2012) The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Lett 325:139-146.
35. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, and Bonner WM (1998) DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858-5868. (Pubitemid 28124064
36. Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, and Russo GL (2013) ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Biochem Pharmacol 85:927-936.
37. Salmena L, Carracedo A, and Pandolfi PP (2008) Tenets of PTEN tumor suppression. Cell 133:403-414. (Pubitemid 351622014
38. Spender LC and Inman GJ (2012) Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. Mol Cancer Res 10:347-359.
39. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, and Herold-Mende C, et al. (2008) Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27:6646-6656.
40. Tait SW and Green DR (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11:621-632.
41. Thaker NG, McDonald PR, Zhang F, Kitchens CA, Shun TY, Pollack IF, and Lazo JS (2010a) Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets. J Neurosci Methods 185:204-212.
42. Thaker NG, Zhang F, McDonald PR, Shun TY, Lazo JS, and Pollack IF (2010b) Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development. Neurosurg Focus 28:E4.
43. Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, and Lazo JS (2009) Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol 76:1246-1255.
44. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, and Cory S, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399. (Pubitemid 44711953
45. Vogler M, Dinsdale D, Dyer MJ, and Cohen GM (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16:360-367.
46. Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, Dyer MJ, and Cohen GM (2008) A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 15:820-830. (Pubitemid 351524424
47. Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, and Kögel D (2010) The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 8:1002-1016.
48. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, and Korsmeyer SJ (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730. (Pubitemid 32385543
49. Wen PY and Kesari S (2008) Malignant gliomas in adults. N Engl JMed 359:492-507.